Atypical, Levetiracetam-induced Hypersensitivity Syndrome Complicated by Fulminant Liver Failure in a Patient Undergoing Hemodialysis

Intern Med. 2022 Oct 1;61(19):2911-2916. doi: 10.2169/internalmedicine.8985-21. Epub 2022 Feb 26.

Abstract

A 59-year-old man undergoing hemodialysis was administered levetiracetam, after which he developed a systemic rash, high fever, severe liver dysfunction, and leukocytopenia with reactivation of human herpes virus 6. Atypical drug-induced hypersensitivity (DIHS) was diagnosed, and prednisolone was administered at 60 mg/day. However, liver failure rapidly progressed, and the patient died 12 days following treatment. Despite the rarity of DIHS with concomitant fulminant liver failure from levetiracetam and sufficient clearance thereof by hemodialysis, our case suggests that this syndrome may still ensue, resulting in mortality, even in hemodialysis patients. Although no treatment has yet been established, strict monitoring and aggressive treatment may be required.

Keywords: drug induced hypersensitivity; hemodialysis; levetiracetam.

Publication types

  • Case Reports

MeSH terms

  • Drug Hypersensitivity Syndrome* / complications
  • Drug Hypersensitivity Syndrome* / etiology
  • Drug Hypersensitivity* / complications
  • Drug Hypersensitivity* / diagnosis
  • Humans
  • Levetiracetam / adverse effects
  • Liver Failure, Acute* / chemically induced
  • Liver Failure, Acute* / therapy
  • Male
  • Middle Aged
  • Prednisolone
  • Renal Dialysis

Substances

  • Levetiracetam
  • Prednisolone